Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConstruction in ProgressCurrent AssetsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Insight Molecular Diagnostics (IMDX) Total Debt (2020 - 2025)

Insight Molecular Diagnostics (IMDX) has disclosed Total Debt for 6 consecutive years, with $428000.0 as the latest value for Q4 2025.

  • Quarterly Total Debt rose 87.72% to $428000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $428000.0 through Dec 2025, up 87.72% year-over-year, with the annual reading at $428000.0 for FY2025, 87.72% up from the prior year.
  • Total Debt hit $428000.0 in Q4 2025 for Insight Molecular Diagnostics, down from $1.1 million in the prior quarter.
  • In the past five years, Total Debt ranged from a high of $12.3 million in Q2 2021 to a low of $109000.0 in Q3 2022.
  • Historically, Total Debt has averaged $1.5 million across 5 years, with a median of $611500.0 in 2022.
  • Biggest five-year swings in Total Debt: plummeted 95.48% in 2022 and later skyrocketed 2022.94% in 2023.
  • Year by year, Total Debt stood at $1.4 million in 2021, then plummeted by 92.15% to $109000.0 in 2022, then surged by 2022.94% to $2.3 million in 2023, then tumbled by 90.15% to $228000.0 in 2024, then skyrocketed by 87.72% to $428000.0 in 2025.
  • Business Quant data shows Total Debt for IMDX at $428000.0 in Q4 2025, $1.1 million in Q3 2025, and $689000.0 in Q2 2025.